Mono Pharmacare Complete Financial Statements

In FYNone, Mono Pharmacare (MONOPHARMA) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 1.8% and ROE of 9.7%. Full financial statements from FY2023 to FY2025 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see MONOPHARMA stock overview.

3 Years of Data
2025 - 2023

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 1.78% 2025 data
EBITDA Margin 5.33% 2025 data
Operating Margin 5.00% 2025 data
Return on Assets 2.73% 2025 data
Return on Equity 9.68% 2025 data

Balance Sheet Ratios

Current Ratio 4.19 2025 data
Debt to Equity 3.55 2025 data
Equity Ratio 28.18% 2025 data
Asset Turnover 1.54 2025 data

MONOPHARMA Revenue, Net Profit & EBITDA — Year-on-Year Growth

MONOPHARMA YoY (March 2025 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+35.8%
Year-over-Year
Equity Growth
+10.7%
Year-over-Year
Liabilities Growth
+35.8%
Year-over-Year
Operating Cash Flow Growth
+55.6%
Year-over-Year
Financing Cash Flow Growth
-37.5%
Year-over-Year

MONOPHARMA Income Statement — Revenue, EBITDA & Net Profit

Mono Pharmacare revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 1.8%. Explore Mono Pharmacare intrinsic price to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023
Revenue 0 169 122 27
Expenses 0 161 116 26
EBITDA 0 9 6 2
Operating Profit Margin % 0.00% 5.00% 5.00% 6.00%
Depreciation 0 0 0 0
Interest 0 4 3 1
Profit Before Tax 0 5 3 1
Tax 0 1 1 0
Net Profit 0 3 3 1
Earnings Per Share (₹) 0.00 1.75 1.59 0.71

MONOPHARMA Balance Sheet — Assets, Liabilities & Shareholders' Equity

MONOPHARMA total assets ₹110 Cr, total equity ₹31 Cr, total liabilities ₹110 Cr (2025) — ROE 9.7%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023
ASSETS
Total Assets 110 81 63
Current Assets 109 80 61
Fixed Assets 1 1 1
Capital Work in Progress 0 0 0
Investments 0 0 0
Other Assets 109 80 62
LIABILITIES
Total Liabilities 110 81 63
Current Liabilities 26 17 18
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 31 28 13
Share Capital 18 18 12
Reserves & Surplus 14 10 1

MONOPHARMA Cash Flow Statement — Operating, Investing & Financing

Mono Pharmacare operating cash flow ₹-4 Cr, investing ₹0 Cr, financing ₹5 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023
Operating Activities -4 -9 -28
Investing Activities 0 0 -1
Financing Activities 5 8 30
Net Cash Flow 0 0 0